BreMel/TNF alpha (Targa Therapeutics)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameBreMel/TNF alpha (Targa Therapeutics)

Drug Alias NameBreMel/TNF-a (Targa Therapeutics)ZME-018 antibody fragment/TNF alpha (Targa Therapeutics)scFvMel/TNF alpha (Targa Therapeutics)scFvMel/TNF-a (Targa Therapeutics)aka scFvMel/TNF (Targa Therapeutics)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionTumor necrosis factor receptor agonists

TargetsTumor necrosis factor receptor

Therapy Area/IndicationsBreast NeoplasmsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesTarga Therapeutics Corp

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTarga Therapeutics Corp

Active IndicationsN/A

Inactive IndicationsBreast NeoplasmsMelanoma

Other Information

ATC CodeN/A